In October 2023, WIXBIO welcomed an official visit from Dr Geoffery, Managing Director, and Dr Nicky, Sales Director of Atlantis Pharmaceuticals from Kenya. This visit is an essential step for both parties to strengthen their partnership further and is crucial for WIXBIO to deepen its presence in the African market.
High-level exchanges to deepen cooperation cooperation intention
During the visit, Dr. Geoffery and Dr. Nicky had a detailed understanding of WIXBIO’s background, core technology, and product lines and visited WIXBIO’s core production plant, where WIXBIO’s technical team showed the guests the company’s innovative capability and production process in the field of animal vaccines, and Dr Geoffery and Dr Nicky expressed their appreciation for WIXBIO’s efforts in vaccine research and development, vaccine production and vaccine manufacturing. Dr. Geoffery and Dr. Nicky highly appreciated WIXBIO’s strict management and professionalism in vaccine R&D, production process, and quality control.
Impressive factory tour During the visit
Dr. Geoffery and Dr. Nicky were impressed by WIXBIO’s advanced production equipment and high-standard production environment, which strictly follows the GMP certification process to ensure that each batch of vaccine products meets international quality standards. At every stage of the production line, WIXBIO carries out strict quality testing, from the procurement of raw materials to the delivery of final products, to ensure the safety and effectiveness of the products.
Especially in vaccine research and development
WIXBIO’s technical team demonstrated the company’s research results and independent innovation ability. WIXBIO not only focuses on routine vaccine research and development but also devotes itself to customizing vaccines according to the characteristics of diseases in different regions to better meet the needs of the global market. Dr. Geoffery and Dr. Nicky recognized WIXBIO’s all-around vaccine research, development, and production capability. They expressed their appreciation to both parties for their cooperation in vaccine research and development. Dr. Geoffery and Dr. Nicky recognize WIXBIO’s all-around vaccine development and production capabilities and look forward to future collaboration between the two companies.
Cooperation between the two parties and looking forward to the future
During the subsequent discussion, Dr. Geoffery and Dr. Nicky expressed that Atlantis highly valued the opportunity to cooperate with WIXBIO, especially in the context of the growing demand in the East African market, and that WIXBIO’s technological advantages and high-quality products would provide strong support for Atlantis in the local market. The two parties had extensive discussions on future cooperation, including customization of vaccine products, technical support, supply chain optimization, and many other aspects, and reached a consensus.
Dr Geoffery noted: ‘We are very impressed with WIXBIO’s expertise and product quality, especially WIXBIO’s innovative vaccine development and production technology. This provides a stable and efficient vaccine supply chain and a solid foundation for future business expansion in the Kenyan and East African markets.
Dr Nicky added, ‘Through this visit, we have better understood WIXBIO’s production capacity and technological advantages. There is great potential for cooperation between the two parties, and we look forward to working together to drive the animal vaccine business in the African market.’
We are continuously expanding international cooperation, creating the future together.
WIXBIO has always been committed to providing high-quality animal vaccine products to its global customers and has continuously improved the competitiveness of its products in the market through innovative technologies and optimized production processes. In the future, WIXBIO will continue to strengthen in-depth cooperation with agents and partners in various countries and expand more international markets, especially in the strategic layout of Africa and the Middle East.
Through close cooperation with Atlantis and other international partners, WIXBIO will promote the research, development, production, and supply of animal vaccines globally and significantly contribute to global animal health.
